365NEWSX
365NEWSX
Subscribe

Welcome

First Patient Injected With Experimental Cancer-Killing Virus in New Clinical Trial - ScienceAlert

First Patient Injected With Experimental Cancer-Killing Virus in New Clinical Trial - ScienceAlert

First Patient Injected With Experimental Cancer-Killing Virus in New Clinical Trial - ScienceAlert
May 23, 2022 46 secs

The drug candidate, called CF33-hNIS (aka Vaxinia), is what's called an oncolytic virus, a genetically modified virus designed to selectively infect and kill cancer cells while sparing healthy ones.

Eventually, the infected cell bursts, releasing thousands of new virus particles that act as antigens, stimulating the immune system to attack nearby cancer cells.

"Our previous research demonstrated that oncolytic viruses can stimulate the immune system to respond to and kill cancer, as well as stimulate the immune system to be more responsive to other immunotherapies," says City of Hope oncologist and principal investigator Daneng Li.

Nobody knows for sure yet if CF33-hNIS will work the same wonders in people, but if it can, it stands to become only the second FDA-approved oncolytic virus therapy for cancer, following on the heels of a drug called Talimogene laherparepvec (T-VEC), a modified version of the herpes simplex virus, which is used in the treatment of melanoma

Summarized by 365NEWSX ROBOTS

RECENT NEWS

SUBSCRIBE

Get monthly updates and free resources.

CONNECT WITH US

© Copyright 2024 365NEWSX - All RIGHTS RESERVED